Stockreport

Week In Review: ProfoundBio, A Seattle-Suzhou ADC Biotech, Acquired By Genmab For $1.8 Billion [Seeking Alpha]

Genmab A/S - American Depositary Shares  (GMAB) 
PDF China Medical System in-licensed povorcitinib, an oral JAK1 inhibitor, from San Francisco's Incyte for autoimmune and inflammatory dermatologic diseases. Suzhou's Inn [Read more]